A Phase 2 interventional study of G-CSF and plerixafor in Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Genzyme, a Sanofi Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.
Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is one of 5 that started in 2004, is one of 15 in phase 2, and was the 3rd registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 36 across the 19 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
20 studies in Lymphoma, Non-Hodgkin by Sanofi: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 20 studies in Lymphoma, Non-Hodgkin by Sanofi, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2004, is one of 11 in phase 2, and was the 7th registered.
Sanofi’s Lymphoma, Non-Hodgkin studies by the year they started, since 2002.
1 of the studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03125642Masonic Cancer Center, University of MinnesotaAuto Stem Cell Transplant for Lymphoma Patients | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, from their registry updates:
Among Sanofi’s 20 in Lymphoma, Non-Hodgkin:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100). The purpose of this protocol is to determine if plerixafor given after chemotherapy and G-CSF mobilization regimen is safe, if it can increase the circulating levels of peripheral blood stem cells (PBSCs) by ≥ 2-fold before apheresis, and if transplantation with the apheresis product was successful, as measured by time to engraftment of polymorphonuclear leukocytes (PMNs) and platelets (PLTs).
An open label, multi-center, phase 2 study was conducted in patients with MM or NHL who were to be treated with peripheral blood stem cells (PBSC) autologous transplantation. The only change to the standard of care was the addition of plerixafor to a mobilization regimen of chemotherapy and G-CSF. Patients were first given a mobilizing regimen of chemotherapy as per local practice guidelines and G-CSF (at customary doses) and apheresis was performed. After the first apheresis, plerixafor was given at 10PM, 10-11 hours before the second apheresis the next day or in the morning of the second day, 6 hours before the second apheresis. The change in the patient's peripheral CD34+ cell count between the plerixafor dose and the start of apheresis was measured. The apheresis yields on Day 1 and Day 2 were compared.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Abbreviated List):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days. Called 'Cohort A' in protocol, study report and publications.
Drug: G-CSF and plerixafor
Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days. Called 'Cohort B' in protocol, study report and publications.
Drug: G-CSF and plerixafor
Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of \>=10 cells/µL but \<20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days. Called 'Cohort C' in protocol, study report and publications.
Drug: G-CSF and plerixafor
This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery. Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached \>= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms. Called 'Investigational Cohort' in protocol, study report and publications.
Drug: G-CSF and plerixafor
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
G-CSF and plerixafor were administered as described in the treatment arms.
Also known as: Mozobil, AMD3100
Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant
Safety assessment was based on the incidence of adverse event reports. Participant count of AEs (Adverse Events) by severity and by relationship to study drug. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.
Time frame: 13 months
Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL
The fold increase was measured by fluorescence activated cell sorting (FACS) analysis and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).
Time frame: Days 4-5 (first dose of plerixafor to apheresis)
Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant
Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.
Time frame: 2 months
Patients with NHL or MM eligible for the study were recruited from 5 centers in the United States. The first patient was enrolled (signed informed consent) in April 2004 and the last patient's last study visit was July 2006.
| Milestone | Non-Hodgkin's Lymphoma (NHL) | Multiple Myeloma (MM) |
|---|---|---|
| Started | 14 | 26 |
| Completed | 14 | 25 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Non-Hodgkin's Lymphoma (NHL) | Multiple Myeloma (MM) |
|---|---|---|
| Started | 14 | 26 |
| Completed | 12 | 23 |
| Not completed | 2 | 3 |
| Withdrew: Final assessment not done | 1 | 3 |
| Withdrew: Death | 1 | 0 |
Safety assessment was based on the incidence of adverse event reports. Participant count of AEs (Adverse Events) by severity and by relationship to study drug. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.
| participants | Non-Hodgkin's Lymphoma (NHL): Plerixafor PM | Non-Hodgkin's Lymphoma (NHL): Plerixafor AM | Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo | Multiple Myeloma (MM): Plerixafor PM | Multiple Myeloma (MM): Plerixafor AM | Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM | Multiple Myeloma (MM): Plerixafor After Chemo | All Participants |
|---|---|---|---|---|---|---|---|---|
| Participants reporting ≥ 1 Adverse Event | 7 | 6 | 1 | 12 | 9 | 1 | 3 | 39 |
| AE Severity (Mild) | 3 | 3 | 0 | 2 | 2 | 0 | 0 | 10 |
| AE Severity (Moderate) | 2 | 1 | 1 | 6 | 3 | 0 | 2 | 15 |
| AE Severity (Severe) | 2 | 2 | 0 | 4 | 4 | 1 | 1 | 14 |
| AE Severity (Life Threatening) | 1 | 1 | 0 | 2 | 3 | 0 | 0 | 7 |
| AE Relationship to Drug (Not related) | 0 | 5 | 0 | 0 | 2 | 0 | 2 | 9 |
| AE Relationship to Drug (Probably not related) | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 6 |
| AE Relationship to Drug (Possibly related) | 1 | 0 | 0 | 3 | 5 | 0 | 0 | 9 |
| AE Relationship to Drug (Probably related) | 1 | 1 | 1 | 3 | 1 | 0 | 0 | 7 |
| AE Relationship to Drug (Definitely related) | 2 | 0 | 0 | 3 | 1 | 1 | 1 | 8 |
The fold increase was measured by fluorescence activated cell sorting (FACS) analysis and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).
| ratio | Non-Hodgkin's Lymphoma (NHL): Plerixafor PM | Non-Hodgkin's Lymphoma (NHL): Plerixafor AM | Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo | Multiple Myeloma (MM): Plerixafor PM | Multiple Myeloma (MM): Plerixafor AM | Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM | Multiple Myeloma (MM): Plerixafor After Chemo |
|---|---|---|---|---|---|---|---|
| Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL | 2.2 ± 0.8 | 1.5 ± 0.8 | 1.2 ± 0.0 | 1.8 ± 0.4 | 6.5 ± 14.7 | 24.0 ± 0.0 | 3.1 ± 0.0 |
Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.
| transplants | Non-Hodgkin's Lymphoma (NHL): Plerixafor PM | Non-Hodgkin's Lymphoma (NHL): Plerixafor AM | Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo | Multiple Myeloma (MM): Plerixafor PM | Multiple Myeloma (MM): Plerixafor AM | Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM | Multiple Myeloma (MM): Plerixafor After Chemo |
|---|---|---|---|---|---|---|---|
| ≤ Day 12 | 6 | 4 | 0 | 14 | 9 | 1 | 0 |
| Day 13 to Day 21 | 1 | 2 | 1 | 0 | 3 | 1 | 4 |
| ≥ Day 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Treatment Period includes the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This period includes G-CSF administration, the plerixafor dose, and the rest period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-Hodgkin's Lymphoma (NHL): Plerixafor PM | — | 1/7 (14.3%) | 7/7 (100%) |
| Non-Hodgkin's Lymphoma (NHL): Plerixafor AM | — | 0/6 (0%) | 6/6 (100%) |
| Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo | — | 0/1 (0%) | 1/1 (100%) |
| Multiple Myeloma (MM): Plerixafor PM | — | 2/12 (16.7%) | 12/12 (100%) |
| Multiple Myeloma (MM): Plerixafor AM | — | 2/9 (22.2%) | 9/9 (100%) |
| Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM | — | 0/1 (0%) | 1/1 (100%) |
| Multiple Myeloma (MM): Plerixafor After Chemo | — | 1/4 (25%) | 2/4 (50%) |
| Event | Non-Hodgkin's Lymphoma (NHL): Plerixafor PM | Non-Hodgkin's Lymphoma (NHL): Plerixafor AM | Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo | Multiple Myeloma (MM): Plerixafor PM | Multiple Myeloma (MM): Plerixafor AM | Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM | Multiple Myeloma (MM): Plerixafor After Chemo |
|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/7 | 0/6 | 0/1 | 1/12 | 2/9 | 0/1 | 1/4 |
| Staphylococcal sepsisInfections and infestations | 1/7 | 0/6 | 0/1 | 0/12 | 0/9 | 0/1 | 0/4 |
| NauseaGastrointestinal disorders | 0/7 | 0/6 | 0/1 | 1/12 | 0/9 | 0/1 | 0/4 |
| VomitingGastrointestinal disorders | 0/7 | 0/6 | 0/1 | 1/12 | 0/9 | 0/1 | 0/4 |
| Cystitis haemorrhagicRenal and urinary disorders | 0/7 | 0/6 | 0/1 | 1/12 | 0/9 | 0/1 | 0/4 |
| Event | Non-Hodgkin's Lymphoma (NHL): Plerixafor PM | Non-Hodgkin's Lymphoma (NHL): Plerixafor AM | Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo | Multiple Myeloma (MM): Plerixafor PM | Multiple Myeloma (MM): Plerixafor AM | Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM | Multiple Myeloma (MM): Plerixafor After Chemo |
|---|---|---|---|---|---|---|---|
| Vision blurredEye disorders | 0/7 | 0/6 | 0/1 | 0/12 | 0/9 | 1/1 | 0/4 |
| Anal fistulaGastrointestinal disorders | 0/7 | 0/6 | 1/1 | 0/12 | 0/9 | 0/1 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 2/7 | 1/6 | 0/1 | 6/12 | 3/9 | 1/1 | 0/4 |
| HaemorrhoidsGastrointestinal disorders | 0/7 | 0/6 | 1/1 | 0/12 | 0/9 | 0/1 | 0/4 |
| Hypoaesthesia oralGastrointestinal disorders | 1/7 | 0/6 | 0/1 | 1/12 | 1/9 | 1/1 | 0/4 |
| Rectal fissureGastrointestinal disorders | 0/7 | 0/6 | 1/1 | 0/12 | 0/9 | 0/1 | 0/4 |
| Catheter site erythemaGeneral disorders | 0/7 | 0/6 | 1/1 | 0/12 | 0/9 | 0/1 | 0/4 |
| Injection site urticariaGeneral disorders | 0/7 | 0/6 | 0/1 | 0/12 | 0/9 | 1/1 | 0/4 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/7 | 0/6 | 1/1 | 1/12 | 0/9 | 0/1 | 0/4 |
| HeadacheNervous system disorders | 5/7 | 0/6 | 1/1 | 2/12 | 3/9 | 1/1 | 0/4 |
| Age, Continuous(years) | Non-Hodgkin's Lymphoma (NHL) | Multiple Myeloma (MM) | Total |
|---|---|---|---|
| Mean | 54.7 ± 10.8 | 56.1 ± 7.6 | 55.6 ± 8.7 |
| Sex: Female, Male(Participants) | Non-Hodgkin's Lymphoma (NHL) | Multiple Myeloma (MM) | Total |
|---|---|---|---|
| Female | 8 | 11 | 19 |
| Male | 6 | 15 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Non-Hodgkin's Lymphoma (NHL) | Multiple Myeloma (MM) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 14 | 24 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Apr 2004, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor